title: [Evaluation of the seroprotection against measles, rubella and hepatitis B in children under 5 years of age in Peru, 2011].
abstract: OBJECTIVE
  To estimate the prevalence of antibodies against measles, rubella and hepatitis B in children aged between 1 and 4 years in Peru.
  
  
  METHODS
  A national survey was conducted based on a questionnaire and capillary blood sample taken on filter paper in order to study antibodies against measles, rubella and hepatitis B in children from 1 to 4 years of age. A stratified, multistage, probability sampling design was used to be representative at the national level and at level of seven ambits, including the Metropolitan Lima Area, the rest of the urban coast, the rural coast, the urban highlands, the rural highlands, the urban jungle and the rural jungle. The capillary blood samples were processed according to the standardized protocols for detection of antibodies using the ELISA technique and commercial reagents.
  
  
  RESULTS
  The survey showed a national prevalence of antibodies against measles, rubella and hepatitis B of 91.6% (CI 95%: 90.6%; 92.7%), 91.3% (CI 95%: 90.3%; 92.4%) and 95.9% (CI 95%: 95.0%; 96.8%) respectively. There was no evidence of significant differences in the prevalence among the ambits of study or among the socioeconomic strata of the conglomerates for any of the three types of antibodies.
  
  
  CONCLUSIONS
  In children from 1 to 4 years of age, the national prevalence of antibodies against measles and Rubella was between 90-93%, while the prevalence of antibodies against Hepatitis B (anti-HBsAg) was between 95-97%.
authors: Unidad de Análisis y Generación de Evidencias en Salud Pública, Instituto nacional de salud, Lima, Perú. vicfiso@yahoo.es
authors: Víctor
authors: V
authors: Fiestas Solórzano
authors: Marco
authors: M
authors: Gonzáles Noriega
authors: Fabián
authors: F
authors: Fiestas
authors: Edwin
authors: E
authors: Cabezudo
authors: Magna
authors: M
authors: Suárez
authors: Víctor
authors: V
authors: Suárez
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D008297:Male; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology*; D010568:Peru; D012411:Rubella Vaccine / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007074:Immunoglobulin G; D008458:Measles Vaccine; D012411:Rubella Vaccine